| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Financial Officer | EVP, Chief Financial Officer | Chief Financial Officer
1 company
Mark C. Schneyer is EVP, Chief Financial Officer at ACAD. From February 2022 to October 2026, the filings on record show 0 open-market purchases and 28 sales. Mark C. Schneyer's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.5M at current prices.
Our model assigns Mark C. Schneyer a middling insider score of 57/100, based on 28 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -6.0%.
The ACAD filings lean toward selling, a net 153,455 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8, 2025 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 2,708 | $14.82 | $40,132.56 | -4.4% | +48.1% | +60.0% | |
| Mar 26, 2025 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 3,171 | $17.05 | $54,065.55 | -5.3% | +31.6% | +26.1% | |
| Feb 24, 2025 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 773 | $19.96 | $15,429.08 | -1.4% | +13.9% | +26.3% | |
| Nov 19, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 10,259 | $16.81 | $172,453.79 | -16.1% | +21.8% | +42.5% | |
| Aug 19, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sell | 9,733 | $15.28 | $148,720.24 | -18.2% | +8.1% | +58.4% | |
| Jun 10, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 975 | $14.79 | $14,420.25 | -2.7% | +6.0% | +49.2% | |
| May 2, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 3,503 | $16.94 | $59,340.82 | -9.9% | +11.4% | -12.7% | |
| Apr 8, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 2,716 | $17.87 | $48,534.92 | -8.6% | -8.3% | -20.8% | |
| Mar 27, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sell | 5,434 | $17.90 | $97,268.60 | -17.2% | -14.3% | -5.5% | |
| Feb 26, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 772 | $24.67 | $19,045.24 | -3.5% | -41.7% | -26.6% |